Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
May 9, 2017 7:00 AM EDTLAVAL, Quebec, May 9, 2017 /PRNewswire/ --
First Quarter Financial Results Revenues of $2.109 Billion GAAP Net Income of $628 Million GAAP Cash Flow from Operations of $954 Million Adjusted EBITDA (non-GAAP) of $861 Million Adjusted Net Income (non-GAAP) of $273 Million Reduced Debt by $1.3 Billion in the quarter Raising 2017 Full Year Adjusted EBITDA Guidance RangeMay 9, 2017 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX)... More
